Get the Stockscreener App
1.90
5.47%
-0.11
After Hours:
1.81
-0.09
-4.74%
Entera Bio Ltd stock is traded at $1.90, with a volume of 52,543.
It is down -5.47% in the last 24 hours and up +13.77% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
See More
Previous Close:
$2.01
Open:
$1.98
24h Volume:
52,543
Relative Volume:
1.15
Market Cap:
$71.58M
Revenue:
$134.00K
Net Income/Loss:
$-9.93M
P/E Ratio:
-5.1351
EPS:
-0.37
Net Cash Flow:
$-6.72M
1W Performance:
-0.52%
1M Performance:
+13.77%
6M Performance:
+13.77%
1Y Performance:
+162.07%
1-Day Range:
$1.90
$2.01
1-Week Range:
$1.8303
$2.02
52-Week Range:
$0.52
$3.35
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data - MSN
Entera Bio shares hold Buy rating on OXM study success By Investing.com - Investing.com South Africa
Entera Bio shares hold Buy rating on OXM study success By Investing.com - Investing.com Australia
Entera Bio shares hold Buy rating on OXM study success - Investing.com
Entera Bio's (ENTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com Australia
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com South Africa
Entera Bio and OPKO Health report promising obesity treatment study - Investing.com
Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders - XM
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com UK
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders - Yahoo Finance
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? - MSN
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? - MSN
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Yahoo Finance
Entera Bio to Participate in Upcoming Investor and Scientific Conferences - GlobeNewswire
Entera Bio to Participate in Upcoming Investor and Scientific Conferences - StockTitan
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy - Yahoo Finance
Entera Bio Ltd. Forecasted to Earn Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:ENTX) - Defense World
Entera Bio Ltd. to Post Q3 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:ENTX) - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 51.0% in July - MarketBeat
Entera Bio (NASDAQ:ENTX) Releases Earnings Results - MarketBeat
Entera Bio's (ENTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Entera Bio (NASDAQ:ENTX) - Defense World
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - GlobeNewswire
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - wallstreet:online
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - StockTitan
Virtu Financial LLC Invests $37,000 in Entera Bio Ltd. (NASDAQ:ENTX) - Defense World
Entera Bio Ltd expected to post a loss of 6 cents a shareEarnings Preview - XM
The 10 Best Biotech Stocks Under $5 To Buy For September 2024! - The Stock Dork
Entera Bio shareholders approve executive compensation, board appointments - Investing.com
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual MeetingKey SABRE Update Also Expected - StockTitan
Entera Bio (NASDAQ:ENTX) Trading Up 1.9% - MarketBeat
Entera Bio (NASDAQ:ENTX) Stock Price Up 1.9% - Defense World
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual MeetingKey SABRE Update Also Expected - Yahoo Finance
Entera Bio (NASDAQ:ENTX) & Vericel (NASDAQ:VCEL) Financial Survey - Defense World
Short bowel syndrome Market Positive Outlook: Phase Bio , Orphan Technologies , Zealand Pharma - Newstrail
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years - Markets Insider
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Simply Wall St
Entera Bio (NASDAQ:ENTX) Trading 6% Higher - MarketBeat
Entera Bio (NASDAQ:ENTX) Stock Price Up 6% - Defense World
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for ... - Barchart
Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich - Markets Insider
Head to Head Contrast: Entera Bio (NASDAQ:ENTX) and HilleVax (NASDAQ:HLVX) - Defense World
Aegis Capital initates Entera Bio Ltd (ENTX) rating to a Buy – Knox Daily - Knox Daily
Entera Bio Ltd (ENTX)'s stock rises to 2.11 per share – US Post News - US Post News
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo New Zealand News
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards? - Yahoo Lifestyle Singapore
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 - Markets Insider
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):